(Q34978580)

5 August 2017

title

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma (English)

1 reference

5 August 2017

author

Berta Sanchez-Laorden

Berta Sanchez-Laorden

17

0 references

Lawrence C. Davies

Lawrence Davies

6

0 references

Steven Whittaker

Steven Whittaker

7

0 references

Neil O Carragher

Neil Carragher

19

0 references

Caroline J Springer

Caroline Springer

28

0 references

Alfonso Zambon

Alfonso Zambon

5

0 references

Paul Lorigan

Paul Lorigan

26

0 references

Louise Johnson

14

Louise Johnson

1 reference

5 August 2017

25

Margaret Frame

1 reference

5 August 2017

1

Maria Romina Girotti

1 reference

5 August 2017

Filipa Lopes

2

1 reference

5 August 2017

Natasha Preece

3

1 reference

5 August 2017

Dan Niculescu-Duvaz

4

1 reference

5 August 2017

Grazia Saturno

8

1 reference

5 August 2017

Amaya Viros

9

1 reference

5 August 2017

Malin Pedersen

10

1 reference

5 August 2017

Bart M J M Suijkerbuijk

11

1 reference

5 August 2017

Delphine Menard

12

1 reference

5 August 2017

Robert McLeary

13

1 reference

5 August 2017

Laura Fish

15

1 reference

5 August 2017

Sarah Ejiama

16

1 reference

5 August 2017

Juliane Hohloch

18

1 reference

5 August 2017

Kenneth Macleod

20

1 reference

5 August 2017

Garry Ashton

21

1 reference

5 August 2017

Anna A Marusiak

22

1 reference

5 August 2017

Alberto Fusi

23

1 reference

5 August 2017

John Brognard

24

1 reference

5 August 2017

Richard Marais

27

1 reference

5 August 2017

publication date

11 December 2014

1 reference

5 August 2017

1 reference

5 August 2017

volume

27

1 reference

5 August 2017

issue

1

1 reference

5 August 2017

page(s)

85-96

1 reference

Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma

5 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

MAP kinase pathway alterations in BRAF-mutant melanoma patients with acquired resistance to combined RAF/MEK inhibition

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Nivolumab plus ipilimumab in advanced melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

RAF265 inhibits the growth of advanced human melanoma tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Whole genome sequencing of matched primary and metastatic acral melanomas

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Tracing pathway activities with kinase inhibitors and reverse phase protein arrays

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

COT drives resistance to RAF inhibition through MAP kinase pathway reactivation

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

A novel, selective, and efficacious nanomolar pyridopyrazinone inhibitor of V600EBRAF.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Guidelines for the welfare and use of animals in cancer research

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Development of novel, highly potent inhibitors of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF): increasing cellular potency through optimization of a distal heteroaromatic group

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Oncogenic Braf induces melanocyte senescence and melanoma in mice

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Pyridoimidazolones as novel potent inhibitors of v-Raf murine sarcoma viral oncogene homologue B1 (BRAF).

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

The selectivity of protein kinase inhibitors: a further update

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Novel inhibitors of B-RAF based on a disubstituted pyrazine scaffold. Generation of a nanomolar lead

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Melanoma incidence and mortality in Europe: new estimates, persistent disparities

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Novel hinge binder improves activity and pharmacokinetic properties of BRAF inhibitors

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Novel potent BRAF inhibitors: toward 1 nM compounds through optimization of the central phenyl ring.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4297292

10.1016/J.CCELL.2014.11.006

9 December 2018

Identifiers

DOI

1 reference

5 August 2017

1 reference

5 August 2017

1 reference